Safety and Excellent Pain Relief Effect after Musculoskeletal Pain Embolization

SEOUL,South Korea,March 17,2025 --NEXTBIOMEDICAL CO.,LDT,announced that clinical study results of Nexsphere-F™,a resorbable embolic agent for treating joint pain,have been published in the esteemed Journal of Vascular and Interventional Radiology (JVIR).

Transcatheter arterial embolization with Nexsphere-F™ was used to address a variety of joint disorders,including knee osteoarthritis,frozen shoulders,symptomatic rotator cuff tears,synovitis of the foot joints,and other refractory overuse injuries. This research was spearheaded by Dr. Yuji Okuno,a globally recognized expert and pioneer in embolization treatment for joint pain. Safety and efficacy were reported in 155 patients.

At 6 months,Nexsphere-F™ embolization demonstrated a sustained and substantial reduction of 67% in pain,as assessed using the Numerical Rating Scale,across a broad spectrum of degenerative joint diseases and injuries. Notably,there were no serious adverse events reported in any of the study groups. Post-embolization pain exceeding 7 days occurred in only 5.8%,significantly lower than the rates observed in competing products,in this challenging population.

NEXTBIOMEDICAL's CTO,Eunhye Lee(Ph.D),stated "It holds great significance that the safety and efficacy of Nexsphere-F™ have been further validated in Dr. Okuno's study,a prominent figure in the field. Leveraging these promising results,we intend to intensify our sales strategies in the European market and initiate further clinical trials to broaden the indications of Nexsphere-F™ beyond degenerative joint disease to encompass other joint disorders."

NEXTBIOMEDICAL has received FDA IDE and WCG IRB approval for its pivotal RESORB trial in the United States and is currently recruiting clinical sites. This multicenter study will support FDA approval of Nexsphere-F™ for treatment of painful osteoarthritis,paving the way for its introduction to the U.S. market.

In the meantime,NEXTBIOMEDICAL has already exceeded its Q4 2024 revenue with sales from January and February 2025 alone. The company anticipates a 1.5-fold increase in Q1 2025 revenue compared to the previous quarter,indicating sustained sales growth.